Ignite Creation Date:
2024-05-05 @ 4:41 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00290498
Status:
COMPLETED
Last Update Posted:
2020-06-02
First Post:
2006-02-10
Brief Title:
Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkins Lymphomas in Patients 60 Years Old or Younger
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Lymphoma |
Keywords:
| Name | View |
|---|---|
| Neosar | View |
| Non-Hodgkins Lymphoma | View |
| B-Cell Non-Hodgkins Lymphoma | View |
| Lymphoma | View |
| Cyclophosphamide | View |
| Cytarabine | View |
| Doxorubicin | View |
| Hyper-CVAD | View |
| Methotrexate | View |
| Prednisone | View |
| Rituximab | View |
| Vincristine | View |
| R-CHOP | View |
| R-HCVAD | View |
| Dexamethasone | View |
| Decadron | View |
| Leucovorin | View |
| Ara-C | View |
| Cytosar | View |
| Cytoxan | View |
| DepoCyt | View |
| Cytosine arabinosine hydrochloride | View |
| AD | View |
| Hydroxydaunomycin hydrochloride | View |